London Stock Exchange welcomes Arecor to AIM

London Stock Exchange today welcomes Arecor Therapeutics (“Arecor”) as it begins trading on AIM under the ticker “AREC” having successfully raised £20 million in an oversubscribed raise, giving a market capitalisation at IPO of £62.5 million.

Arecor is a globally focused biopharmaceutical company that is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products.  By applying its innovative proprietary formulation technology platform, Arestat™, Arecor is developing a portfolio of proprietary products and working with leading pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies, supported by an extensive patent portfolio.

The Arestat™ technology, in combination with the extensive know-how of stability requirements, development processes and regulatory requirements, offers a series of formulation options that have been specifically designed to overcome the challenges associated with delivering enhanced pharmaceutical products via reformulation. 

Arecor proprietary product portfolio is currently focused on diabetes and specialty hospital care. For partners, it develops novel enhanced formulations of their biological products that include biosimilars, biological products and vaccines. 

The proceeds will be used to progress the Company’s lead diabetes products, develop and expand its pipeline of specialty hospital Ready-To-Use and Ready-To-Administer products and build the team, as well as bolster working capital and strengthen the balance sheet.

Sarah Howell, Chief Executive Officer of Arecor, said: “Today represents an important milestone for Arecor and we are delighted to be listing on AIM.  This IPO will allow us to continue to grow the business through the development of our own proprietary diabetes and specialty hospital products whilst creating further value through our technology licensing partnerships. We were delighted by the support and interest we received during this transaction which is testament to the potential of our innovative proprietary formulation technology platform, Arestat™. I would like to take this opportunity to thank our new and existing shareholders for their support and we are looking forward to embarking on this next exciting chapter in the Company’s development.”

Andrew Richards, Chairman of Arecor, commented: “Arecor’s technology and expertise has been validated through multiple partnerships with major pharmaceutical and biotechnology companies. The Company also has a balanced business model that offers the potential for significant returns associated with successful drug development but with reduced development risk through development of existing approved therapeutics products and partnering. As someone who has always championed the London market and has supported UK life-science companies to IPO in London I am very pleased Arecor has chosen to list on AIM. Led by a strong team and Board, Arecor has the potential to become a significant UK biopharmaceutical company and deliver benefits to patients and clinicians.” 

Advisers to the IPO: 

Panmure Gordon (UK) Limited, Nominated Advisor and Sole Broker to the Company 
Covington & Burling LLP, Legal Advisers
Grant Thornton, Reporting Accountant
Consilium Communications, Financial PR Advisers

Quick facts

Track
Market: AIM
Instrument market cap (£m)
104.38
Listing/Admission to trading
03 Jun 2021
Looking for new and recent issues?

More recent

92.5
London Stock Exchange welcomes Graft Polymer Plc to the Main Market

The London Stock Exchange today welcomes Graft Polymer (UK) PLC, a business focused on the development of polymer modification, bio/food supplements and drug delivery systems, to the Main Market, trading under the ticker symbol “GPL”.

Graft Polymer is an early-stage company with a state-of-the-art polymer research and development, manufa

Learn more
97.567
London Stock Exchange welcomes Genflow Biosciences Plc to the Main Market

London Stock Exchange today welcomes Genflow Biosciences Plc, a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age, to the Standard Listing Segment of the Main Market, under the ticker symbol "GENF".

Genflow Biosciences opened th

Learn more
74.96
London Stock Exchange welcomes East Star Resources Plc and their readmission to the Main Market

London Stock Exchange welcomes the readmission of East Star Resources, a company focused on the discovery and development of gold, copper, and base metals in Kazakhstan, to the Main Market under the ticker “EST”. The company raised gross proceeds of £3.1 million via a placing and subscription of 62,000,000 shares at £0.05 per share, delivering a ma

Learn more
168
London Stock Exchange celebrates FTSE Russell’s index partnership with Abu Dhabi Securities Exchange

Today, London Stock Exchange markets were opened by Abu Dhabi Securities Exchange and FTSE Russell to mark their partnership and the launch of the FTSE ADX Index Series.

FTSE ADX General Index FTSE ADX Sector Indexes FTSE Russell provides daily index calculations on the ADX General Index FTSE ADX General Index replaces the ADX General Index FTSE Russ

Learn more